PharmasteP R A C T I C E

PHARMASTE · POCKET GUIDE

Medication safety & toxicology

Study essentials · Version 2 · Reviewed

Focused adult pharmacy study guide for safer medication systems, high-alert products, overdose recognition and selected antidote concepts. Toxicology content is for learning and urgent recognition, not a standalone bedside poisoning protocol. Actual exposures require emergency support and a poison center or toxicologist; pediatric, pregnancy and comprehensive poison-specific dosing are outside this guide.

Put it into practice

1. Build safeguards around the work

  • High-alert status reflects the severity of harm when an error occurs; it does not mean that errors must occur more often. Standardize concentrations, storage and workflows, and restrict access when appropriate.
  • Use selected independent double checks deliberately: each person works from the original order and actual product before comparing results. A check is one safeguard, not a substitute for safer system design.
  • Test new product barcodes, scan the actual patient and product, and use a defined escalation pathway for failures. Proxy barcodes can create a false appearance of verification.
  • Prefer ready-to-administer preparations when appropriate. Do not repurpose saline flush syringes to dilute IV medications; follow the product-specific preparation and administration requirements.
  • After an event, reconstruct the workflow and identify contributing conditions. Choose actions that address those conditions, assign responsibility and measure implementation and recurrence.

Pause & recall
Why is a second signature not necessarily an independent double check?

Sources: ISMP: High-Alert Medications in Acute Care Settings · ISMP: Three new 2026–2027 hospital medication safety best practices · ISMP: Independent double checks · AHRQ PSNet: Root Cause Analysis

2. Pause at product, dose and route mismatches

Swipe or scroll to read the full table.

Pause at product, dose and route mismatches
RiskSafe learning pointCommon trap
Concentrated insulin penThe U-500 KwikPen displays actual units; no dose conversion. Never withdraw insulin from the pen into a syringe.Applying a U-100 syringe conversion to the dedicated pen.
Weekly oral methotrexateFor a verified weekly regimen, state the exact day and check that all directions agree.Daily directions for an intended weekly regimen can be fatal.
Fentanyl patchAvoid direct heat over the patch and surrounding skin.A low heating-pad setting or a towel does not make external heat safe.
EpinephrineVerify the indication, route, concentration and prescribed dose together.An IM anaphylaxis dose is not an IV arrest or infusion regimen.
Dose notationUse a leading zero for doses below one; avoid an unnecessary trailing zero. Write units clearly.0.5 mg is safer than .5 mg; 5 mg is safer than 5.0 mg.

Pause & recall
Which insulin unit number should a U-500 KwikPen display for a prescribed 90-unit dose?

Sources: HUMULIN R U-500 KwikPen U.S. prescribing information · Methotrexate tablets U.S. prescribing information · Fentanyl transdermal system U.S. prescribing information · ADRENALIN epinephrine injection 1 mg/mL U.S. prescribing information · ISMP: Error-prone abbreviations, symbols and dose designations

3. Reconcile, counsel and report

  • Collect prescription, nonprescription and supplement use; compare what the patient actually takes with the intended plan. Clarify omissions, duplications, dose changes and stop instructions with the responsible clinician.
  • A documented switch still needs a usable transition plan. Resolve conflicting anticoagulant directions before dispensing rather than assuming an overlap is intentional.
  • Check active ingredients across pain, sleep and cold products. Count acetaminophen from all products and avoid unintended simultaneous acetaminophen-containing medicines.
  • Report suspected serious drug adverse events and product-use problems through appropriate organizational processes and FDA MedWatch. Report relevant post-vaccination events to VAERS even when causality is uncertain; a report alone does not prove the vaccine caused the event.

Pause & recall
What should be resolved before a patient leaves with two conflicting anticoagulant instructions?

Sources: AHRQ PSNet: Medication Reconciliation · FDA: Acetaminophen safety information · FDA: Reporting serious problems · CDC: Vaccine Adverse Event Reporting System

4. Recognize the emergency before refining the diagnosis

  • Collapse, seizure or inadequate breathing require emergency response. Support airway, breathing and circulation; naloxone must not delay necessary ventilation or CPR.
  • Collect the product/container, route, time, possible amount and co-exposures without delaying help. In the United States, Poison Control is 1-800-222-1222. Do not induce vomiting or wait for symptoms to decide whether an uncertain exposure needs assessment.
  • An exposure cluster with headache or nausea near a fuel-burning source suggests CO. Conventional pulse oximetry may look normal despite poisoning; arrange emergency oxygen and co-oximetry-based assessment.
  • Gray-blue skin and dyspnea after benzocaine raise concern for acquired methemoglobinemia. Stop further exposure and obtain urgent evaluation rather than treating the color as a cosmetic effect.

Pause & recall
Can a normal conventional pulse-oximeter reading exclude carbon monoxide poisoning?

Sources: NIH MedlinePlus: Poisoning first aid · 2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation · CDC: Clinical Guidance for Carbon Monoxide Poisoning · FDA letter regarding benzocaine-associated methemoglobinemia

5. Match the exposure to a selected treatment concept

Swipe or scroll to read the full table.

Match the exposure to a selected treatment concept
Exposure or syndromeSelected treatment conceptBoundary
AcetaminophenAcetylcysteine when indicatedUse the appropriate acute or repeated-exposure pathway.
Severe salicylate poisoningIV sodium bicarbonate while arranging urgent hemodialysis assessmentAltered mental status, pulmonary edema or acidemia can drive escalation; do not rely on concentration alone.
Opioid respiratory depressionNaloxone plus respiratory supportEffects may recur after an initial response.
Life-threatening digoxin toxicityDigoxin immune FabFollow clinical response, ECG and potassium.
Suspected cyanide poisoningHydroxocobalaminParticularly relevant in severe smoke-inhalation presentations.
Methanol or ethylene glycolFomepizole; assess need for hemodialysisSpecialist management depends on exposure, acidosis, organ injury and concentrations.
Organophosphate syndromeAtropine; pralidoxime when indicatedDecontamination precautions and ventilation remain essential.
TCA or other sodium-channel-blocker cardiotoxicitySodium bicarbonate for life-threatening sodium-channel cardiotoxicityUse monitored toxicology-guided treatment, not a routine dose for every ingestion.
LAST with severe neurologic or cardiovascular toxicityIV lipid emulsion and modified resuscitationUse the current ASRA checklist with expert support.
Severe beta-blocker or calcium-channel-blocker poisoningHigh-dose insulin may be part of specialist-directed treatmentRequires close glucose, potassium and hemodynamic monitoring.

Pause & recall
Which treatments address a toxin while resuscitation and monitoring continue?

Sources: ACETADOTE acetylcysteine injection U.S. prescribing information · NARCAN naloxone nasal spray U.S. prescribing information · DIGIFAB U.S. prescribing information · CYANOKIT hydroxocobalamin U.S. prescribing information · Fomepizole U.S. prescribing information · 2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation · ASRA: Local anesthetic systemic toxicity checklist · ACMT: Management priorities in salicylate toxicity · EXTRIP: Salicylates

6. Know when a familiar shortcut fails

  • The acute acetaminophen nomogram is not a tool for repeated supratherapeutic ingestion or an unknown ingestion time. An early level before 4 hours after an acute ingestion can be misleading. History, hepatic tests and urgent treatment decisions still matter.
  • The current ACETADOTE label includes two-bag and three-bag IV regimens. Select one complete regimen, verify eligibility and dilution, and do not combine their dose schedules.
  • Finishing a fixed acetylcysteine infusion schedule is not by itself a stopping rule. Reassess acetaminophen concentration, hepatic injury, INR and the clinical course; some patients need continued treatment with toxicology guidance.
  • Flumazenil is unsuitable as a routine reversal drug in an unknown mixed overdose, chronic benzodiazepine exposure or important seizure/arrhythmia risk. Selected pure benzodiazepine cases require careful assessment.
  • IV methylene blue is contraindicated in G6PD deficiency and has a serious serotonin-syndrome warning with serotonergic medicines and opioids. Emergency benefit–risk decisions need specialist input.
  • After naloxone, continue surveillance and emergency care. If breathing fails to improve or depression recurs, repeat with a new nasal device according to the product instructions, generally every 2–3 minutes while help is arriving.

Pause & recall
Why can the acute acetaminophen nomogram be inappropriate even when a concentration is available?

Sources: ACETADOTE acetylcysteine injection U.S. prescribing information · PROVAYBLUE methylene blue U.S. prescribing information · 2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation · NARCAN naloxone nasal spray U.S. prescribing information · ACMT: Duration of IV acetylcysteine after acetaminophen overdose — 2026 update

7. Interpret laboratory results and monitor after antidotes

Swipe or scroll to read the full table.

Interpret laboratory results and monitor after antidotes
After treatmentInterpretation issueAction
Digoxin immune FabRoutine total digoxin measurements can include Fab-bound drug and become misleading.Prioritize clinical status, ECG and potassium; seek expert advice for suspected recurrence.
HydroxocobalaminRed color can interfere with selected assays and trigger false dialysis blood-leak alarms.Notify laboratory and dialysis teams; effects vary by method and equipment.
Methylene blueNew agitation, hyperthermia or neuromuscular findings may indicate serotonin toxicity.Assess promptly and follow the treating team’s interaction/monitoring plan.

Pause & recall
Does a high total digoxin level after Fab automatically mean more antidote is needed?

Sources: DIGIFAB U.S. prescribing information · CYANOKIT hydroxocobalamin U.S. prescribing information · PROVAYBLUE methylene blue U.S. prescribing information

8. Calculate the dose, then check the delivery

Swipe or scroll to read the full table.

Calculate the dose, then check the delivery
Verified order and supplyWorked calculationSafety check
Heparin 1,200 units/hour; 25,000 units/250 mL final volume100 units/mL; 1,200 ÷ 100 = 12 mL/hourCompare the original order, actual bag and pump program independently.
Epinephrine 0.3 mg IM; 1 mg/mL vial0.3 ÷ 1 = 0.3 mLConfirm route and concentration before preparing.
Three-bag acetylcysteine first dose 150 mg/kg; 70 kg; stock 200 mg/mL150 × 70 = 10,500 mg; 10,500 ÷ 200 = 52.5 mL stockDilute and infuse as ordered; 52.5 mL is not the final admixture volume.

Pause & recall
Which calculated volume is stock solution rather than the final infusion volume?

Sources: ISMP: Independent double checks · ADRENALIN epinephrine injection 1 mg/mL U.S. prescribing information · ACETADOTE acetylcysteine injection U.S. prescribing information

Abbreviations

TCA
tricyclic antidepressant
CPR
cardiopulmonary resuscitation
IV
intravenous
IM
intramuscular
OTC
over the counter
ECG
electrocardiogram
INR
international normalized ratio
G6PD
glucose-6-phosphate dehydrogenase
SSRI
selective serotonin reuptake inhibitor
CO
carbon monoxide
NAC
N-acetylcysteine, also called acetylcysteine
Fab
antigen-binding antibody fragment
LAST
local anesthetic systemic toxicity
RCA
root cause analysis
VAERS
Vaccine Adverse Event Reporting System
ISMP
Institute for Safe Medication Practices

Sources & verification

Guide reviewed . Source checks are dated below. These selected teaching points use the guidance and product references below. Confirm current labeling, the patient's circumstances, and local protocols before applying a regimen.

  1. ISMP: High-Alert Medications in Acute Care Settings — Definition and enhanced safeguards · Checked https://home.ecri.org/blogs/guidance-insights-tools/high-alert-medications-in-acute-care-settings
  2. ISMP: Three new 2026–2027 hospital medication safety best practices — Best practices 23–25: IV push safety, barcode use and culture of safety · Checked https://home.ecri.org/blogs/guidance-insights-tools/survey-shows-room-for-improvement-with-three-new-best-practices-for-hospitals-1
  3. ISMP: Independent double checks — Selective use; independent calculations before comparison; limitations · Checked https://home.ecri.org/blogs/guidance-insights-tools/independent-double-checks-worth-the-effort-if-used-judiciously-and-properly
  4. AHRQ PSNet: Root Cause Analysis — Systems approach; event reconstruction; effective actions and implementation · Checked https://psnet.ahrq.gov/primer/root-cause-analysis
  5. HUMULIN R U-500 KwikPen U.S. prescribing information — 2.3 and 17: dose window, no conversion, no transfer into a syringe · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b60e8dd0-1d48-4dc9-87fd-e14675255e8c
  6. Methotrexate tablets U.S. prescribing information — 5.9: fatal daily-versus-weekly dosing errors · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=874c7f43-a3be-4236-89cc-24c44e3c5813
  7. Fentanyl transdermal system U.S. prescribing information — Boxed warning and 5.8: external heat and overdose; patient counseling · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a2238e9-4b5d-c56d-8663-dd354ff9ae0c
  8. ADRENALIN epinephrine injection 1 mg/mL U.S. prescribing information — 2.2: adult anaphylaxis dosing; 3: concentration · Checked https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b293ad8e-7055-4a95-a130-9d7d74f19eab&type=display
  9. ISMP: Error-prone abbreviations, symbols and dose designations — Safer communication across handwritten and electronic settings · Checked https://home.ecri.org/blogs/guidance-insights-tools/list-of-error-prone-abbreviations
  10. AHRQ PSNet: Medication Reconciliation — Background and accomplishing medication reconciliation at transitions of care · Checked https://psnet.ahrq.gov/primer/medication-reconciliation
  11. FDA: Acetaminophen safety information — Avoid simultaneous acetaminophen-containing products; read active ingredients and directions · Checked https://www.fda.gov/drugs/safe-use-over-counter-pain-relievers-and-fever-reducers/acetaminophen
  12. FDA: Reporting serious problems — MedWatch voluntary reporting of suspected adverse events and product problems · Checked https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
  13. CDC: Vaccine Adverse Event Reporting System — Reporting adverse events; temporal association does not establish causation · Checked https://www.cdc.gov/vaccine-safety-systems/vaers/index.html
  14. NIH MedlinePlus: Poisoning first aid — Immediate response, information to collect and actions to avoid · Checked https://medlineplus.gov/ency/article/007579.htm
  15. 2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation — Adult poisoning sections: opioids, cardiac glycosides, cyanide, organophosphates, sodium-channel blockers and local anesthetics · Checked https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/adult-and-pediatric-special-circumstances-of-resuscitation
  16. CDC: Clinical Guidance for Carbon Monoxide Poisoning — Management and confirmation of diagnosis; conventional pulse oximetry limitations · Checked https://www.cdc.gov/carbon-monoxide/hcp/clinical-guidance/index.html
  17. FDA letter regarding benzocaine-associated methemoglobinemia — Safety risk and warning language for oral benzocaine products · Checked https://www.fda.gov/files/drugs/published/FDA-Letter-Regarding-Benzocaine.pdf
  18. ACETADOTE acetylcysteine injection U.S. prescribing information — 2.1–2.6: assessment, nomogram limitations, two- and three-bag regimens; 3: 200 mg/mL · Checked https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39
  19. NARCAN naloxone nasal spray U.S. prescribing information — 2.1–2.2 and 5.1: single-use device, repeat doses and recurrent respiratory depression · Checked https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=76b5a1ce-e601-457c-ab35-43533bba4394
  20. DIGIFAB U.S. prescribing information — 5: misleading post-treatment total digoxin concentrations and clinical/potassium monitoring · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c05ee6a5-c98b-45f4-83fd-40781639d653
  21. CYANOKIT hydroxocobalamin U.S. prescribing information — 2.3, 5.5: compatibility, laboratory interference and dialysis blood-leak alarms · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d56fcc8d-bd64-46ab-b0c0-2124bd745a6b
  22. Fomepizole U.S. prescribing information — Indications and usage; toxic alcohol poisoning and hemodialysis considerations · Checked https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7e133194-dacb-446a-a657-2d2430a02373
  23. ASRA: Local anesthetic systemic toxicity checklist — 2020 checklist; lipid emulsion and modified resuscitation · Checked https://asra.com/news-publications/asra-updates/blog-landing/guidelines/2020/11/01/checklist-for-treatment-of-local-anesthetic-systemic-toxicity
  24. ACMT: Management priorities in salicylate toxicity — Alkalinization and indications for hemodialysis · Checked https://www.acmt.net/wp-content/uploads/2022/06/PRS_130313_Management-Priorities-in-Salicylate-Toxicity.pdf
  25. EXTRIP: Salicylates — Extracorporeal treatment indications and continued IV bicarbonate · Checked https://www.extrip-workgroup.org/salicylates
  26. PROVAYBLUE methylene blue U.S. prescribing information — Boxed warning, 4, 5.1 and 7: serotonin syndrome, G6PD deficiency and interacting medicines · Checked https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6848e5-35ed-4046-b13c-3032b5ba3232
  27. ACMT: Duration of IV acetylcysteine after acetaminophen overdose — 2026 update — Reassessment of acetaminophen, hepatic injury, INR and clinical course before stopping · Checked https://www.acmt.net/news/acmt-practice-statement-duration-of-intravenous-acetylcysteine-therapy-following-acetaminophen-overdose-2026-update/

Original Pharmaste educational material. Not affiliated with or endorsed by NABP. © 2026 Pharmaste.